caffeine has been researched along with Amaurosis in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004." | 9.16 | Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012) |
| "3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004." | 5.16 | Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012) |
| "Caffeine treatment significantly improved daytime alertness at adverse circadian phases (p <0." | 2.80 | Caffeine does not entrain the circadian clock but improves daytime alertness in blind patients with non-24-hour rhythms. ( Lockley, SW; St Hilaire, MA, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| St Hilaire, MA | 1 |
| Lockley, SW | 1 |
| Pagano, CW | 1 |
| Wu, M | 1 |
| Wu, L | 1 |
| Schmidt, B | 1 |
| Anderson, PJ | 1 |
| Doyle, LW | 1 |
| Dewey, D | 1 |
| Grunau, RE | 1 |
| Asztalos, EV | 1 |
| Davis, PG | 1 |
| Tin, W | 1 |
| Moddemann, D | 1 |
| Solimano, A | 1 |
| Ohlsson, A | 1 |
| Barrington, KJ | 1 |
| Roberts, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants[NCT00182312] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1999-10-31 | Completed | ||
| Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia[NCT05295784] | Phase 1 | 18 participants (Anticipated) | Interventional | 2024-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for caffeine and Amaurosis
| Article | Year |
|---|---|
Acute visual loss and intraretinal hemorrhages associated to energy drink consumption.
Topics: Blindness; Caffeine; Diagnosis, Differential; Energy Drinks; Humans; Male; Middle Aged; Retinal Hemo | 2017 |
2 trials available for caffeine and Amaurosis
| Article | Year |
|---|---|
Caffeine does not entrain the circadian clock but improves daytime alertness in blind patients with non-24-hour rhythms.
Topics: Affect; Aged; Arousal; Blindness; Caffeine; Circadian Clocks; Humans; Male; Melatonin; Middle Aged; | 2015 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |